DUBLIN–(BUSINESS WIRE)–The “Global Bioprosthetic Heart Valves Market 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The global bioprosthetic heart valves market is anticipated to grow at a substantial CAGR of 11.4% during the forecast period. Ongoing improvements and development in the healthcare facilities are supporting the implantation of the bioprosthetic heart valve in developing countries which in turns driving the market growth during the forecast period.
For instance, the most recent development in bioprosthetic heart valves technology is the percutaneous (or transcatheter) valve replacement, which involves replacement of the aortic valve in a minimally invasive procedure with catheterization from a large blood vessel, most commonly the femoral artery. However, high cost of these procedures, as well as a lack of skilled professionals, hinders the market growth. Additionally, governments’ stringent regulations for product approval have been hindering the market growth.
The global bioprosthetic heart valves market is segmented based on the type, and end-user. Based on the type, the market is segmented into homograft, heterograft, bovine pericardial valve, and stent-less valves. Based on, the end-user the market is sub-segmented into hospitals, research institutes, and other. On the basis of end user, hospital segment is projected to exhibit the fastest growth in the global bioprosthetic heart valves market over the forecast period. The growth attributed to the availability of various surgical procedures in such settings.
For instance, in 2021, CARMAT announced the first implant of its Aeson bioprosthetic artificial heart in a commercial setting. This implant of the Aeson artificial heart was performed at the Azienda Ospedalieradei Colli hospital in Naples. 5 German hospitals have already been trained by CARMAT and are currently screening patients for an implant.
Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is predicted to be the fastest growing region due to rising geriatric population and increasing incidence and prevalence rate of heart diseases. According to American College of Cardiology Foundation, over half of all CVD deaths globally in 2019 occurred in Asian countries and from 1990 to 2019, the number of CVD deaths in Asia rose from 5.6 million to 10.8 million.
The major companies serving the global bioprosthetic heart valves market include Medtronic International Trading Sarl, TTK Healthcare Ltd., Edwards Lifesciences Corp., Boston Scientific Corp., Abbott Laboratories and others.
The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in 2021 St. Jude Medical, Inc. a global medical device company announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) and the launch of the Trifecta aortic stented, pericardial tissue valve. The first procedures were performed at Osaka University Hospital and Saitama Medical University International Medical Center in Japan.
The Report Covers
- Comprehensive research methodology of the global bioprosthetic heart valves market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global bioprosthetic heart valves market.
- Insights about market determinants that are stimulating the global bioprosthetic heart valves market.
- Detailed and extensive market segments with the regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Bioprosthetic Heart Valves Market by Type
4.1.1. Homograft
4.1.2. Heterograft
4.1.3. Bovine Pericardial Valve
4.1.4. Stent-less Valves
4.2. Global Bioprosthetic Heart Valves Market by End-User
4.2.1. Hospitals
4.2.2. Research Institutes
4.2.3. Other
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Boston Scientific Corp.
6.3. BraileBiomedica
6.4. Colibri Heart Valve LLC
6.5. Edwards Lifesciences Corp.
6.6. enVVeno Medical
6.7. Jenavalve Technology Gmbh
6.8. LivaNova PLC
6.9. Medtronic International Trading Sarl
6.10. TTK Healthcare Ltd.
6.11. Symetis SA
6.12. Cryolife Inc.
6.13. Lepu Medical Technology Co. Ltd.
6.14. Foldax, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/69629v
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
